<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999400</url>
  </required_header>
  <id_info>
    <org_study_id>FDA-SOL-1120920</org_study_id>
    <secondary_id>HHSF223201300460A</secondary_id>
    <secondary_id>HHSF223201000082C</secondary_id>
    <nct_id>NCT01999400</nct_id>
  </id_info>
  <brief_title>Correlation of Mesalamine Pharmacokinetics With Local Availability</brief_title>
  <official_title>Correlation of Mesalamine Pharmacokinetics With Local Availability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <brief_summary>
    <textblock>
      This study is designed to provide data to the FDA correlating pharmacokinetics with local
      availability of medications within the gastrointestinal tract. This study will support the
      establishment of scientifically based standards for evaluating drugs which act locally within
      the gastrointestinal tract. Specific objectives of this study are to: (1) quantify how the
      plasma concentrations of mesalamine, an agent used to treat inflammatory bowel disease, are
      correlated with the concentrations in gastrointestinal fluids; and (2) improve the
      physiologically based models for drug absorption from the intestine. Information from this
      study in concert with in vitro dissolution data will be used to evaluate in vivo-in vitro
      correlation (IVIVC) for concentrations in plasma and intestinal lumen and dissolution of
      mesalamine products.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluated the pharmacokinetics of mesalamine and its major metabolite of
      mesalamine known as N-acetyl-mesalamine in plasma. Mesalamine is available in different
      formulations that control the rate at which they are released in the gastrointestinal tract.
      Three formulations of mesalamine, Pentasa, Apriso, and Lialda, were studied in the crossover
      phase, while an oral solution formulation of mesalamine was studied in the single-arm phase.
      Each subject participated in a crossover phase study with one of the three formulations
      assigned at random using block randomization. Then the subject entered the single-arm phase
      study. After participation in one crossover phase study and one single-arm phase study, the
      subject could opt to participate in crossover phase studies using the other formulations also
      chosen at random until all three formulations were studied. The single-arm phase study was
      not repeated on returning subjects who participated in more than one crossover phase study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The AUC of Mesalamine in Plasma</measure>
    <time_frame>0 hours pre-dose and up to 96 hours post-dose</time_frame>
    <description>The AUC is the area under the concentration-time curve from time 0 to last time point. The data are organized by the different drug formulations of mesalamine, which include Pentasa (0 to 72 hours), Apriso (0 to 72 hours), Lialda (0 to 96 hours), and Delzicol (0 to 24 hours). The AUC is measured in units of nanomoles of mesalamine per liter of plasma (nM) multiplied by time in hours (nM*h). The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The AUC of Metabolite (N-acetyl-mesalamine) in Plasma</measure>
    <time_frame>0 hours pre-dose and up to 96 hours post-dose</time_frame>
    <description>The AUC is the area under the concentration-time curve from time 0 to last time point. The data are organized by the different drug formulations of mesalamine, which include Pentasa (0 to 72 hours), Apriso (0 to 72 hours), Lialda (0 to 96 hours), and Delzicol (0 to 24 hours). The AUC is measured in units of nanomoles of N-acetyl-mesalamine per liter of plasma (nM) multiplied by time in hours (nM*h). The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The AUC of Mesalamine in Distal Jejunum</measure>
    <time_frame>0 hours pre-dose and up to 7 hours post-dose</time_frame>
    <description>The AUC is the area under the concentration-time curve from time 0 to 7 hours. The data are organized by the different drug formulations of mesalamine, which include Pentasa, Apriso, and Lialda. The AUC is measured in units of micromoles of mesalamine per liter of plasma (µM) multiplied by time in hours (µM*h).The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations. The solution formulation (Delzicol) was not administered in this portion of the study. Therefore no results pertaining to the solution formulation are included in this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The AUC of Metabolite (N-acetyl-mesalamine) in Distal Jejunum</measure>
    <time_frame>0 hours pre-dose and up to 7 hours post-dose</time_frame>
    <description>The AUC is the area under the concentration-time curve from time 0 to 7 hours. The data are organized by the different drug formulations of mesalamine, which include Pentasa, Apriso, and Lialda. The AUC is measured in units of micromoles of mesalamine per liter of plasma (µM) multiplied by time in hours (µM*h).The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations. The solution formulation (Delzicol) was not administered in this portion of the study. Therefore no results pertaining to the solution formulation are included in this outcome measure.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Local Drug Concentration in Gastrointestinal Tract</condition>
  <arm_group>
    <arm_group_label>Arm 1: Pentasa then Delzicol then Apriso then Lialda</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pentasa 500 mg capsule x 2 with 240 mL water, single dose.
Washout period of 10 days.
Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
Washout period of 10 days.
Apriso 375 mg capsule x 3 with 240 mL water, single dose.
Washout period of 10 days.
Lialda 1200 mg tablet x 1 with 240 mL water, single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Pentasa then Delzicol then Lialda then Apriso</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pentasa 500 mg capsule x 2 with 240 mL water, single dose.
Washout period of 10 days.
Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
Washout period of 10 days.
Lialda 1200 mg tablet x 1 with 240 mL water, single dose.
Washout period of 10 days.
Apriso 375 mg capsule x 3 with 240 mL water, single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Apriso then Delzicol then Pentasa then Lialda</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apriso 375 mg capsule x 3 with 240 mL water, single dose.
Washout period of 10 days.
Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
Washout period of 10 days.
Pentasa 500 mg capsule x 2 with 240 mL water, single dose.
Washout period of 10 days.
Lialda 1200 mg tablet x 1 with 240 mL water, single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Apriso then Delzicol then Lialda then Pentasa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apriso 375 mg capsule x 3 with 240 mL water, single dose.
Washout period of 10 days.
Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
Washout period of 10 days.
Lialda 1200 mg tablet x 1 with 240 mL water, single dose.
Washout period of 10 days.
Pentasa 500 mg capsule x 2 with 240 mL water, single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5: Lialda then Delzicol then Pentasa then Apriso</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lialda 1200 mg tablet x 1 with 240 mL water, single dose.
Washout period of 10 days.
Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
Washout period of 10 days.
Pentasa 500 mg capsule x 2 with 240 mL water, single dose.
Washout period of 10 days.
Apriso 375 mg capsule x 3 with 240 mL water, single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6: Lialda then Delzicol then Apriso then Pentasa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lialda 1200 mg tablet x 1 with 240 mL water, single dose.
Washout period of 10 days.
Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
Washout period of 10 days.
Apriso 375 mg capsule x 3 with 240 mL water, single dose.
Washout period of 10 days.
Pentasa 500 mg capsule x 2 with 240 mL water, single dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentasa 500 mg capsule x 2 with 240 mL water; single dose</intervention_name>
    <arm_group_label>Arm 1: Pentasa then Delzicol then Apriso then Lialda</arm_group_label>
    <arm_group_label>Arm 2: Pentasa then Delzicol then Lialda then Apriso</arm_group_label>
    <arm_group_label>Arm 3: Apriso then Delzicol then Pentasa then Lialda</arm_group_label>
    <arm_group_label>Arm 4: Apriso then Delzicol then Lialda then Pentasa</arm_group_label>
    <arm_group_label>Arm 5: Lialda then Delzicol then Pentasa then Apriso</arm_group_label>
    <arm_group_label>Arm 6: Lialda then Delzicol then Apriso then Pentasa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apriso 375 mg capsule x 3 with 240 mL water; single dose</intervention_name>
    <arm_group_label>Arm 1: Pentasa then Delzicol then Apriso then Lialda</arm_group_label>
    <arm_group_label>Arm 2: Pentasa then Delzicol then Lialda then Apriso</arm_group_label>
    <arm_group_label>Arm 3: Apriso then Delzicol then Pentasa then Lialda</arm_group_label>
    <arm_group_label>Arm 4: Apriso then Delzicol then Lialda then Pentasa</arm_group_label>
    <arm_group_label>Arm 5: Lialda then Delzicol then Pentasa then Apriso</arm_group_label>
    <arm_group_label>Arm 6: Lialda then Delzicol then Apriso then Pentasa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lialda 1200 mg tablet x 1 with 240 mL water; single dose</intervention_name>
    <arm_group_label>Arm 1: Pentasa then Delzicol then Apriso then Lialda</arm_group_label>
    <arm_group_label>Arm 2: Pentasa then Delzicol then Lialda then Apriso</arm_group_label>
    <arm_group_label>Arm 3: Apriso then Delzicol then Pentasa then Lialda</arm_group_label>
    <arm_group_label>Arm 4: Apriso then Delzicol then Lialda then Pentasa</arm_group_label>
    <arm_group_label>Arm 5: Lialda then Delzicol then Pentasa then Apriso</arm_group_label>
    <arm_group_label>Arm 6: Lialda then Delzicol then Apriso then Pentasa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose</intervention_name>
    <arm_group_label>Arm 1: Pentasa then Delzicol then Apriso then Lialda</arm_group_label>
    <arm_group_label>Arm 2: Pentasa then Delzicol then Lialda then Apriso</arm_group_label>
    <arm_group_label>Arm 3: Apriso then Delzicol then Pentasa then Lialda</arm_group_label>
    <arm_group_label>Arm 4: Apriso then Delzicol then Lialda then Pentasa</arm_group_label>
    <arm_group_label>Arm 5: Lialda then Delzicol then Pentasa then Apriso</arm_group_label>
    <arm_group_label>Arm 6: Lialda then Delzicol then Apriso then Pentasa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Adults age 18 to 55.

          2. Male or female voluntarily able to give informed consent.

          3. Body mass index (BMI) 18.5 to 35.

        Exclusion Criteria

          1. Adults unable to consent for themselves or mentally incapacitated.

          2. Prisoners.

          3. Significant clinical illness within 3 weeks prior to Screening.

          4. Use of concomitant medications within 2 weeks prior to receiving study drug, including
             but not limited to prescription drugs, herbal and dietary supplements, over the
             counter medications, and vitamins. Oral contraception is permitted.

          5. History of gastrointestinal surgery.

          6. History of allergy to non-steroidal anti-inflammatory drugs (NSAIDs) or to any of the
             ingredients of Asacol, Pentasa, Apriso, or Lialda.

          7. History of severe allergic diseases including drug allergies, with the exception of
             seasonal allergies.

          8. Any other factor, condition, or disease, including, but not limited to,
             cardiovascular, renal, hepatic, or gastrointestinal disorders that may, in the opinion
             of the Investigator, jeopardize the safety of the patient or impact the validity of
             the study results.

          9. History of drug addiction or alcohol abuse within the past 12 months.

         10. Pregnant or lactating females.

         11. Surgery within the past 3 months.

         12. Received an investigational drug within 60 days prior to receiving the study drug.

         13. Any clinically significant abnormal lab values during Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duxin Sun, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan, College of Pharmacy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lionberger RA. FDA critical path initiatives: opportunities for generic drug development. AAPS J. 2008;10(1):103-9. doi: 10.1208/s12248-008-9010-2. Epub 2008 Feb 20. Review.</citation>
    <PMID>18446510</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <results_first_submitted>November 7, 2016</results_first_submitted>
  <results_first_submitted_qc>May 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 15, 2017</results_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Duxin Sun</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Pentasa Then Delzicol Then Apriso Then Lialda</title>
          <description>Pentasa 500 mg capsule x 2 with 240 mL water, single dose.
Washout period of 10 days.
Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
Washout period of 10 days.
Apriso 375 mg capsule x 3 with 240 mL water, single dose.
Washout period of 10 days.
Lialda 1200 mg tablet x 1 with 240 mL water, single dose.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Pentasa Then Delzicol Then Lialda Then Apriso</title>
          <description>Pentasa 500 mg capsule x 2 with 240 mL water, single dose.
Washout period of 10 days.
Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
Washout period of 10 days.
Lialda 1200 mg tablet x 1 with 240 mL water, single dose.
Washout period of 10 days.
Apriso 375 mg capsule x 3 with 240 mL water, single dose.</description>
        </group>
        <group group_id="P3">
          <title>Arm 3: Apriso Then Delzicol Then Pentasa Then Lialda</title>
          <description>Apriso 375 mg capsule x 3 with 240 mL water, single dose.
Washout period of 10 days.
Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
Washout period of 10 days.
Pentasa 500 mg capsule x 2 with 240 mL water, single dose.
Washout period of 10 days.
Lialda 1200 mg tablet x 1 with 240 mL water, single dose.</description>
        </group>
        <group group_id="P4">
          <title>Arm 4: Apriso Then Delzicol Then Lialda Then Pentasa</title>
          <description>Apriso 375 mg capsule x 3 with 240 mL water, single dose.
Washout period of 10 days.
Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
Washout period of 10 days.
Lialda 1200 mg tablet x 1 with 240 mL water, single dose.
Washout period of 10 days.
Pentasa 500 mg capsule x 2 with 240 mL water, single dose.</description>
        </group>
        <group group_id="P5">
          <title>Arm 5: Lialda Then Delzicol Then Pentasa Then Apriso</title>
          <description>Lialda 1200 mg tablet x 1 with 240 mL water, single dose.
Washout period of 10 days.
Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
Washout period of 10 days.
Pentasa 500 mg capsule x 2 with 240 mL water, single dose.
Washout period of 10 days.
Apriso 375 mg capsule x 3 with 240 mL water, single dose.</description>
        </group>
        <group group_id="P6">
          <title>Arm 6: Lialda Then Delzicol Then Apriso Then Pentasa</title>
          <description>Lialda 1200 mg tablet x 1 with 240 mL water, single dose.
Washout period of 10 days.
Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose.
Washout period of 10 days.
Apriso 375 mg capsule x 3 with 240 mL water, single dose.
Washout period of 10 days.
Pentasa 500 mg capsule x 2 with 240 mL water, single dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Fourth Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants who were randomized to one of the six arms of this study:
Arm 1: Pentasa then Delzicol then Apriso then Lialda Arm 2: Pentasa then Delzicol then Lialda then Apriso Arm 3: Apriso then Delzicol then Pentasa then Lialda Arm 4: Apriso then Delzicol then Lialda then Pentasa Arm 5: Lialda then Delzicol then Pentasa then Apriso Arm 6: Lialda then Delzicol then Apriso then Pentasa</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.9" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg per m squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The AUC of Mesalamine in Plasma</title>
        <description>The AUC is the area under the concentration-time curve from time 0 to last time point. The data are organized by the different drug formulations of mesalamine, which include Pentasa (0 to 72 hours), Apriso (0 to 72 hours), Lialda (0 to 96 hours), and Delzicol (0 to 24 hours). The AUC is measured in units of nanomoles of mesalamine per liter of plasma (nM) multiplied by time in hours (nM*h). The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations.</description>
        <time_frame>0 hours pre-dose and up to 96 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentasa</title>
            <description>Pentasa 500 mg capsule x 2 with 240 mL water, single dose
Pentasa 500 mg capsule x 2 with 240 mL water; single dose</description>
          </group>
          <group group_id="O2">
            <title>Apriso</title>
            <description>Apriso 375 mg capsule x 3 with 240 mL water, single dose
Apriso 375 mg capsule x 3 with 240 mL water; single dose</description>
          </group>
          <group group_id="O3">
            <title>Lialda</title>
            <description>Lialda 1200 mg tablet x 1 with 240 mL water, single dose
Lialda 1200 mg tablet x 1 with 240 mL water; single dose</description>
          </group>
          <group group_id="O4">
            <title>Delzicol</title>
            <description>Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose
Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC of Mesalamine in Plasma</title>
          <description>The AUC is the area under the concentration-time curve from time 0 to last time point. The data are organized by the different drug formulations of mesalamine, which include Pentasa (0 to 72 hours), Apriso (0 to 72 hours), Lialda (0 to 96 hours), and Delzicol (0 to 24 hours). The AUC is measured in units of nanomoles of mesalamine per liter of plasma (nM) multiplied by time in hours (nM*h). The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations.</description>
          <units>nM*h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8" spread="29.5"/>
                    <measurement group_id="O2" value="57.6" spread="24.1"/>
                    <measurement group_id="O3" value="36.8" spread="16.0"/>
                    <measurement group_id="O4" value="7.9" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The AUC of Metabolite (N-acetyl-mesalamine) in Plasma</title>
        <description>The AUC is the area under the concentration-time curve from time 0 to last time point. The data are organized by the different drug formulations of mesalamine, which include Pentasa (0 to 72 hours), Apriso (0 to 72 hours), Lialda (0 to 96 hours), and Delzicol (0 to 24 hours). The AUC is measured in units of nanomoles of N-acetyl-mesalamine per liter of plasma (nM) multiplied by time in hours (nM*h). The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations.</description>
        <time_frame>0 hours pre-dose and up to 96 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pentasa</title>
            <description>Pentasa 500 mg capsule x 2 with 240 mL water, single dose
Pentasa 500 mg capsule x 2 with 240 mL water; single dose</description>
          </group>
          <group group_id="O2">
            <title>Apriso</title>
            <description>Apriso 375 mg capsule x 3 with 240 mL water, single dose
Apriso 375 mg capsule x 3 with 240 mL water; single dose</description>
          </group>
          <group group_id="O3">
            <title>Lialda</title>
            <description>Lialda 1200 mg tablet x 1 with 240 mL water, single dose
Lialda 1200 mg tablet x 1 with 240 mL water; single dose</description>
          </group>
          <group group_id="O4">
            <title>Delzicol</title>
            <description>Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose
Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC of Metabolite (N-acetyl-mesalamine) in Plasma</title>
          <description>The AUC is the area under the concentration-time curve from time 0 to last time point. The data are organized by the different drug formulations of mesalamine, which include Pentasa (0 to 72 hours), Apriso (0 to 72 hours), Lialda (0 to 96 hours), and Delzicol (0 to 24 hours). The AUC is measured in units of nanomoles of N-acetyl-mesalamine per liter of plasma (nM) multiplied by time in hours (nM*h). The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations.</description>
          <units>nM*h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162" spread="59.7"/>
                    <measurement group_id="O2" value="189" spread="92.2"/>
                    <measurement group_id="O3" value="124" spread="80.5"/>
                    <measurement group_id="O4" value="20.4" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUC of Mesalamine in Distal Jejunum</title>
        <description>The AUC is the area under the concentration-time curve from time 0 to 7 hours. The data are organized by the different drug formulations of mesalamine, which include Pentasa, Apriso, and Lialda. The AUC is measured in units of micromoles of mesalamine per liter of plasma (µM) multiplied by time in hours (µM*h).The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations. The solution formulation (Delzicol) was not administered in this portion of the study. Therefore no results pertaining to the solution formulation are included in this outcome measure.</description>
        <time_frame>0 hours pre-dose and up to 7 hours post-dose</time_frame>
        <population>The number of subjects that were administered Pentasa, Apriso, Lialda were 10, 7, and 9, respectively. However, we were only able to collect gastrointestinal fluid from the distal jejunum for only 3 subjects in each of these arms due to the placement of the gastrointestinal tube.</population>
        <group_list>
          <group group_id="O1">
            <title>Pentasa</title>
            <description>Pentasa 500 mg capsule x 2 with 240 mL water, single dose
Pentasa 500 mg capsule x 2 with 240 mL water; single dose</description>
          </group>
          <group group_id="O2">
            <title>Apriso</title>
            <description>Apriso 375 mg capsule x 3 with 240 mL water, single dose
Apriso 375 mg capsule x 3 with 240 mL water; single dose</description>
          </group>
          <group group_id="O3">
            <title>Lialda</title>
            <description>Lialda 1200 mg tablet x 1 with 240 mL water, single dose
Lialda 1200 mg tablet x 1 with 240 mL water; single dose</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC of Mesalamine in Distal Jejunum</title>
          <description>The AUC is the area under the concentration-time curve from time 0 to 7 hours. The data are organized by the different drug formulations of mesalamine, which include Pentasa, Apriso, and Lialda. The AUC is measured in units of micromoles of mesalamine per liter of plasma (µM) multiplied by time in hours (µM*h).The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations. The solution formulation (Delzicol) was not administered in this portion of the study. Therefore no results pertaining to the solution formulation are included in this outcome measure.</description>
          <population>The number of subjects that were administered Pentasa, Apriso, Lialda were 10, 7, and 9, respectively. However, we were only able to collect gastrointestinal fluid from the distal jejunum for only 3 subjects in each of these arms due to the placement of the gastrointestinal tube.</population>
          <units>uM*h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8456" spread="7444"/>
                    <measurement group_id="O2" value="4923" spread="8506"/>
                    <measurement group_id="O3" value="2.9" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The AUC of Metabolite (N-acetyl-mesalamine) in Distal Jejunum</title>
        <description>The AUC is the area under the concentration-time curve from time 0 to 7 hours. The data are organized by the different drug formulations of mesalamine, which include Pentasa, Apriso, and Lialda. The AUC is measured in units of micromoles of mesalamine per liter of plasma (µM) multiplied by time in hours (µM*h).The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations. The solution formulation (Delzicol) was not administered in this portion of the study. Therefore no results pertaining to the solution formulation are included in this outcome measure.</description>
        <time_frame>0 hours pre-dose and up to 7 hours post-dose</time_frame>
        <population>The number of subjects that were administered Pentasa, Apriso, Lialda were 10, 7, and 9, respectively. However, we were only able to collect gastrointestinal fluid from the distal jejunum for only 3 subjects in each of these arms due to the placement of the gastrointestinal tube.</population>
        <group_list>
          <group group_id="O1">
            <title>Pentasa</title>
            <description>Pentasa 500 mg capsule x 2 with 240 mL water, single dose
Pentasa 500 mg capsule x 2 with 240 mL water; single dose</description>
          </group>
          <group group_id="O2">
            <title>Apriso</title>
            <description>Apriso 375 mg capsule x 3 with 240 mL water, single dose
Apriso 375 mg capsule x 3 with 240 mL water; single dose</description>
          </group>
          <group group_id="O3">
            <title>Lialda</title>
            <description>Lialda 1200 mg tablet x 1 with 240 mL water, single dose
Lialda 1200 mg tablet x 1 with 240 mL water; single dose</description>
          </group>
        </group_list>
        <measure>
          <title>The AUC of Metabolite (N-acetyl-mesalamine) in Distal Jejunum</title>
          <description>The AUC is the area under the concentration-time curve from time 0 to 7 hours. The data are organized by the different drug formulations of mesalamine, which include Pentasa, Apriso, and Lialda. The AUC is measured in units of micromoles of mesalamine per liter of plasma (µM) multiplied by time in hours (µM*h).The AUC results are reported over the time-period because this provides a more meaningful comparison of potential differences in the bioequivalence of formulations. The solution formulation (Delzicol) was not administered in this portion of the study. Therefore no results pertaining to the solution formulation are included in this outcome measure.</description>
          <population>The number of subjects that were administered Pentasa, Apriso, Lialda were 10, 7, and 9, respectively. However, we were only able to collect gastrointestinal fluid from the distal jejunum for only 3 subjects in each of these arms due to the placement of the gastrointestinal tube.</population>
          <units>uM*h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5048" spread="5553"/>
                    <measurement group_id="O2" value="1225" spread="2024"/>
                    <measurement group_id="O3" value="3.4" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pentasa</title>
          <description>Pentasa 500 mg capsule x 2 with 240 mL water, single dose
Pentasa 500 mg capsule x 2 with 240 mL water; single dose</description>
        </group>
        <group group_id="E2">
          <title>Apriso</title>
          <description>Apriso 375 mg capsule x 3 with 240 mL water, single dose
Apriso 375 mg capsule x 3 with 240 mL water; single dose</description>
        </group>
        <group group_id="E3">
          <title>Lialda</title>
          <description>Lialda 1200 mg tablet x 1 with 240 mL water, single dose
Lialda 1200 mg tablet x 1 with 240 mL water; single dose</description>
        </group>
        <group group_id="E4">
          <title>Delzicol</title>
          <description>Delzicol 100 mg mesalamine x 1 with 245 mL water, single dose
Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>vasovagal syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Evaluation of healthy volunteers that may not reflect patients with inflammatory bowel disease.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Duxin Sun</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-763-9783</phone>
      <email>pharmacy.research@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

